Anticancer Activity of Measles-Mumps-Rubella MMR Vaccine Viruses Against Glioblastoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Sep 9

PMID 37686579

Authors

Zumama Khalid

Simona Coco

Nadir Ullah

Alessandra Pulliero

Katia Cortese

Serena Varesano

Andrea Orsi

Alberto Izzotti

Affiliations

Soon will be listed here.

Abstract

Background: Oncolytic viruses (OVs) have been utilized since 1990s for targeted cancer treatment. Our study examined the Measles-Mumps-Rubella (MMR) vaccine's cancer-killing potency against Glioblastoma (GBM), a therapy-resistant, aggressive cancer type.

Methodology: We used GBM cell lines, primary GBM cells, and normal mice microglial cells, to assess the MMR vaccine's efficacy through cell viability, cell cycle analysis, intracellular viral load via RT-PCR, and Transmission Electron Microscopy (TEM).

Results: After 72 h of MMR treatment, GBM cell lines and primary GBM cells exhibited significant viability reduction compared to untreated cells. Conversely, normal microglial cells showed only minor changes in viability and morphology. Intracellular viral load tests indicated GBM cells' increased sensitivity to MMR viruses compared to normal cells. The cell cycle study also revealed measles and mumps viruses' crucial role in cytopathic effects, with the rubella virus causing cell cycle arrest.

Conclusion: Herein the reported results demonstrate the anti-cancer activity of the MMR vaccine against GBM cells. Accordingly, the MMR vaccine warrants further study as a potential new tool for GBM therapy and relapse prevention. Therapeutic potential of the MMR vaccine has been found to be promising in earlier studies as well.

Citing Articles

Clinical characteristics and survival outcomes in patients with pulmonary sarcomatoid carcinoma: a multicenter retrospective study.

Du Z, Qin Y, Lv Y, Gao J, Chen S, Du X Clin Transl Oncol. 2024; .

PMID: 39720986 DOI: 10.1007/s12094-024-03823-8.

An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.

Stergiopoulos G, Concilio S, Galanis E Curr Treat Options Oncol. 2024; 25(7):952-991.

PMID: 38896326 PMC: 11878440. DOI: 10.1007/s11864-024-01211-6.

The power of mumps virus: Matrix protein activates apoptotic pathways in human colorectal cell lines.

Morovati S, Mohammadi A, Masoudi R, Heidari A, Asad Sangabi M PLoS One. 2023; 18(12):e0295819.

PMID: 38091318 PMC: 10718445. DOI: 10.1371/journal.pone.0295819.

References

Pecora A, Rizvi N, Cohen G, Meropol N, Sterman D, Marshall J . Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002; 20(9):2251-66. DOI: 10.1200/JCO.2002.08.042. View

Srinivasan V, Lang F, Kan P . Intraarterial delivery of virotherapy for glioblastoma. Neurosurg Focus. 2021; 50(2):E7. DOI: 10.3171/2020.11.FOCUS20845. View

Roulstone V, Khan K, Pandha H, Rudman S, Coffey M, Gill G . Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clin Cancer Res. 2014; 21(6):1305-12. PMC: 4821068. DOI: 10.1158/1078-0432.CCR-14-1770. View

Cohn D, Sill M, Walker J, OMalley D, Nagel C, Rutledge T . Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017; 146(3):477-483. PMC: 5570536. DOI: 10.1016/j.ygyno.2017.07.135. View

Rangel M, Karasawa H, Castro N, Nagaoka T, Salomon D, Bianco C . Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. Am J Pathol. 2012; 180(6):2188-200. PMC: 3378914. DOI: 10.1016/j.ajpath.2012.02.031. View

Galanis E, Markovic S, Suman V, Nuovo G, Vile R, Kottke T . Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther. 2012; 20(10):1998-2003. PMC: 3464629. DOI: 10.1038/mt.2012.146. View

Kaufman H, Kohlhapp F, Zloza A . Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015; 14(9):642-62. PMC: 7097180. DOI: 10.1038/nrd4663. View

Chiocca E, Abbed K, Tatter S, Louis D, Hochberg F, Barker F . A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. 2004; 10(5):958-66. DOI: 10.1016/j.ymthe.2004.07.021. View

Nokisalmi P, Pesonen S, Escutenaire S, Sarkioja M, Raki M, Cerullo V . Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res. 2010; 16(11):3035-43. DOI: 10.1158/1078-0432.CCR-09-3167. View

10.

Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I . Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013; 19(10):2734-44. DOI: 10.1158/1078-0432.CCR-12-2546. View

11.

Pilgaard L, Mortensen J, Henriksen M, Olesen P, Sorensen P, Laursen R . Cripto-1 expression in glioblastoma multiforme. Brain Pathol. 2014; 24(4):360-70. PMC: 8029290. DOI: 10.1111/bpa.12131. View

12.

Appolloni I, Alessandrini F, Menotti L, Avitabile E, Marubbi D, Piga N . Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma. Viruses. 2021; 13(9). PMC: 8473268. DOI: 10.3390/v13091677. View

13.

Vidal L, Pandha H, Yap T, White C, Twigger K, Vile R . A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008; 14(21):7127-37. DOI: 10.1158/1078-0432.CCR-08-0524. View

14.

Rudin C, Poirier J, Senzer N, Stephenson Jr J, Loesch D, Burroughs K . Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res. 2011; 17(4):888-95. PMC: 5317273. DOI: 10.1158/1078-0432.CCR-10-1706. View

15.

Todo T, Rabkin S, Chahlavi A, Martuza R . Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther. 1999; 10(17):2869-78. DOI: 10.1089/10430349950016591. View

16.

Feng L, Wang Y, Wang X, An S, Aizimuaji Z, Tao C . Integrated analysis of the rhesus monkey liver transcriptome during development and human primary HCC AFP-related gene expression. Mol Ther Nucleic Acids. 2021; 25:406-415. PMC: 8403716. DOI: 10.1016/j.omtn.2021.06.004. View

17.

Kalyan A, Carneiro B, Chandra S, Kaplan J, Chae Y, Matsangou M . Nodal Signaling as a Developmental Therapeutics Target in Oncology. Mol Cancer Ther. 2017; 16(5):787-792. DOI: 10.1158/1535-7163.MCT-16-0215. View

18.

Barbieri F, Bosio A, Pattarozzi A, Tonelli M, Bajetto A, Verduci I . Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives. J Exp Clin Cancer Res. 2022; 41(1):53. PMC: 8822754. DOI: 10.1186/s13046-021-02213-0. View

19.

Freytag S, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D . Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2014; 89(2):268-76. PMC: 4026796. DOI: 10.1016/j.ijrobp.2014.02.034. View

20.

Khuri F, Nemunaitis J, Ganly I, Arseneau J, Tannock I, Romel L . a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000; 6(8):879-85. DOI: 10.1038/78638. View